Another study which evaluated the addition of palbociclib to endocrine therapy was PALOMA-3, a phase III, randomised (2:1), double-blind, placebo-controlled clinical trial which included 521 patients (regardless of their menopausal status) with advanced breast cancer, positive hormone receptors, and HER-2 negative. Here, NR4A1 is linked to breast carcinoma.